FDA Clears New 7T MRI System from Siemens Healthineers
Offering improved image clarity capable of capturing details of subtle pathology, the Magnetom Terra.X 7T MRI system reportedly features the first eight-channel parallel transmit architecture for clinical use.
The Magnetom Terra.X., a new 7T magnetic resonance imaging (MRI) system, has garnered 510(k) clearance from the Food and Drug Administration (FDA).
A second-generation successor to the Magnetom Terra, the Magnetom Terra.X system has a number of attributes to provide enhanced 7T imaging, according to Siemens Healthineers, the manufacturer of Magnetom Terra.X.
The Magnetom Terra.X system, recently cleared by the FDA, has a number of features including the first eight-channel parallel transmit architecture for clinical use, according to Siemens Healthineers, the manufacturer of the 7T MRI system. (Image courtesy of Siemens Healthineers.)
The company said key features of the device include:
• the first eight-channel parallel transmit architecture for clinical use;
• deep learning image reconstruction specifically geared to 7T;
• improved diffusion imaging via a high-performance gradient system; and
• accelerated image acquisition capabilities that can facilitate high-resolution brain and knee exams in less than 20 minutes.
“The MAGNETOM Terra.X builds on our engineering achievements as pioneers in 7T MRI by providing the ultra-high-field community with the necessary tools to offer higher-quality patient care not just in neurological imaging, but also in the knee,” said Katie Grant, vice president of magnetic resonance at Siemens Healthineers North America.
Siemens Healthineers added that the FDA clearance includes upgrades of installed Magnetom Terra systems to the Magnetom Terra.X.
New bpMRI Study Suggests AI Offers Comparable Results to Radiologists for PCa Detection
April 15th 2025Demonstrating no significant difference with radiologist detection of clinically significant prostate cancer (csPCa), a biparametric MRI-based AI model provided an 88.4 percent sensitivity rate in a recent study.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
Could Ultrafast MRI Enhance Detection of Malignant Foci for Breast Cancer?
April 10th 2025In a new study involving over 120 women, nearly two-thirds of whom had a family history of breast cancer, ultrafast MRI findings revealed a 5 percent increase in malignancy risk for each second increase in the difference between lesion and background parenchymal enhancement (BPE) time to enhancement (TTE).
Study Suggests AI Software May Offer Standalone Value for X-Ray Detection of Pediatric Fractures
April 9th 2025Artificial intelligence (AI) software demonstrated a 92 percent sensitivity for detecting fractures in a study involving over 1,600 X-rays from a tertiary pediatric emergency department.
